Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer

Chest

Volumn 125, Issue 6, 2004, Pages 2300-2308

  Detterbeck, Frank C ^a   Falen, Steven ^a   Rivera, M Patricia ^a   Halle, Jan S ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Lung cancer; Positron emission tomography; Staging

Indexed keywords

BIOPSY; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; MEDIASTINUM; METASTASIS; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SYMPTOM;

EID: 2942738826     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.6.2300     Document Type: Review

References (43)

1. Detterbeck F, Falen S, Rivera M, et al. Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004; 125:2294-2299
2. Gambhir S, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S-92S
3. Pieterman R, VanPutten J, Meuzelaar J, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000; 343:254-261
4. Saunders CAB, Dussek JE, O'Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography in the staging of lung cancer. Ann Thorac Surg 1999; 67:790-797
5. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809
6. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s; meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536
7. 18-F FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed small-cell cell lung cancer. J Nucl Med 2001; 42:1596-1604
8. Valk P, Pounds T, Tesar R, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23:737-743
9. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37:1428-1436
10. Detterbeck FC, Jones DR, Parker LA Jr. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: W.B. Saunders, 2001; 73-93
11. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359:1388-1392
12. Detterbeck FC, Jones DR, Molina PL. Extrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: W.B. Saunders, 2001; 94-110
13. Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97:1052-1058
14. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500
15. Jacobson AF, Cronin EB, Stomper PC, et al. Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. Radiology 1990; 175: 229-232
16. Hatter J, Kohman LJ, Mosca RS, et al. Preoperative evaluation of stage I and stage II non-small cell lung cancer. Ann Thorac Surg 1994; 58:1738-1741
17. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the postoperative assessment of non-small cell lung cancer. Thorax 1988; 43:883-886
18. Guyatt GH, Cook DJ, Griffith LE, et al. Surgeons' assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer. Ann Thorac Surg 1999; 68:309-315
19. Guyatt GH, Lefcoe M, Walter S, et al. Interobserver variation in the computed tomographic evaluation of mediastinal lymph node size in patients with potentially resectable lung cancer. Chest 1995; 107:116-119
20. Staples CA, Müller NL, Miller RR, et al. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 1988; 167:367-372
21. Shen Y-Y, Shiau Y-C, Wang J-J, et al. Whole-body 18F-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res 2002; 22:1257-1264
22. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483-488
23. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25:1244-1247
24. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194:131-134
25. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357-1360
26. Graeber G, Gupta N, Murray G. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999; 117:719-727
27. Gupta NC, Graeber GM, Rogers JS II, et al. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229:286-291
28. Vesselle H, Pugsley JM, Vallières E, et al. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002; 124:511-519
29. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50:287-293
30. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-893
31. Eschmann SM, Friedel G, Paulsen F, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002; 29:804-808
32. Toloza EM, Harpole L, McCrory D. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123:1378-1468
33. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer; priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27:1598-1609
34. Detterbeck FC, DeCamp MMJ, Kohman LJ, et al. Invasive staging: the guidelines. Chest 2003; 123:1678-1758
35. Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small cell lung cancer. Chest 2003; 123:147S-156S
36. Fischer BMB, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659-666
37. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139:879-892
38. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer; FDG PET for nodal staging in patients with stage I disease. Radiology 2000; 215:886-890
39. Reed C, Harpole D, Posther K, et al. Results of the American College of Surgeons Oncology Group (ACOSOG) Z0050 trial: the utility of PET in staging patients with potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1943-1951
40. Ichinose Y, Hara N, Ohta M, et al. Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer: preoperative examination for lung cancer. Chest 1989; 96: 1104-1109
41. Boyer M, Viney R, Fulham M, et al. A randomised trial of conventional staging with or without positron emission tomography (PET) in patients with stage 1 or 2 non-small cell lung cancer (NSCLC). Proc ASCO 2001; 20:309a
42. Kernstine K, McLaughlin K, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall lung cancer? Ann Thorac Surg 2002; 73:394-402
43. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1900-1905